SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Herantis Pharma Says Clinical Evidence Supports HER-096 Phase 2 Study Design

The Phase 2 study will assess HER-096’s efficacy in approximately 100 participants. The body text is truncated after “smartphone-b.”

Related stories